Medivir CEO says JNJ can’t effectively promote two HCV PI’s (Incivek and TMC435): http://www.bloomberg.com/news/2011-07-13/j-j-has-to-resolve-hepatitis-c-drug-conflict-medivir-ceo-says.html Similar to AMLN’s complaint that LLY can’t effectively promote both Tradjenta and Byetta.